IL153567A0 - Dual specificity antibodies and methods of making and using - Google Patents
Dual specificity antibodies and methods of making and usingInfo
- Publication number
- IL153567A0 IL153567A0 IL15356701A IL15356701A IL153567A0 IL 153567 A0 IL153567 A0 IL 153567A0 IL 15356701 A IL15356701 A IL 15356701A IL 15356701 A IL15356701 A IL 15356701A IL 153567 A0 IL153567 A0 IL 153567A0
- Authority
- IL
- Israel
- Prior art keywords
- antibodies
- methods
- alpha
- dual specificity
- beta
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/245—IL-1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21537900P | 2000-06-29 | 2000-06-29 | |
PCT/US2001/020755 WO2002002773A2 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
Publications (1)
Publication Number | Publication Date |
---|---|
IL153567A0 true IL153567A0 (en) | 2003-07-06 |
Family
ID=22802758
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL15356701A IL153567A0 (en) | 2000-06-29 | 2001-06-28 | Dual specificity antibodies and methods of making and using |
IL153567A IL153567A (he) | 2000-06-29 | 2002-12-20 | נוגדנים בעלי ספציפיות דואלית המקשר שני פרוטאינים שונים בעלי מבנה דומה ושיטה להשגתו |
IL203955A IL203955A (he) | 2000-06-29 | 2010-02-14 | נוגדן בעל ספציפיות דואלית הקושר שני פרוטאינים שונים בעלי מבנה דומה ושיטה להשגתו |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL153567A IL153567A (he) | 2000-06-29 | 2002-12-20 | נוגדנים בעלי ספציפיות דואלית המקשר שני פרוטאינים שונים בעלי מבנה דומה ושיטה להשגתו |
IL203955A IL203955A (he) | 2000-06-29 | 2010-02-14 | נוגדן בעל ספציפיות דואלית הקושר שני פרוטאינים שונים בעלי מבנה דומה ושיטה להשגתו |
Country Status (27)
Country | Link |
---|---|
US (5) | US7491516B2 (he) |
EP (4) | EP1297142B1 (he) |
JP (2) | JP4955185B2 (he) |
KR (2) | KR20080074231A (he) |
CN (3) | CN1451043A (he) |
AT (1) | ATE420958T1 (he) |
AU (1) | AU2001271636A1 (he) |
BG (1) | BG66209B1 (he) |
BR (1) | BR0112026A (he) |
CA (1) | CA2411374C (he) |
CZ (1) | CZ2003291A3 (he) |
DE (1) | DE60137421D1 (he) |
EC (1) | ECSP024409A (he) |
ES (1) | ES2319866T3 (he) |
HK (1) | HK1055316A1 (he) |
HU (1) | HUP0301002A3 (he) |
IL (3) | IL153567A0 (he) |
MX (1) | MXPA02012867A (he) |
NO (1) | NO20026239L (he) |
NZ (1) | NZ523080A (he) |
PE (1) | PE20020132A1 (he) |
PL (1) | PL208069B1 (he) |
SK (1) | SK1152003A3 (he) |
TW (2) | TWI307716B (he) |
UY (1) | UY26807A1 (he) |
WO (1) | WO2002002773A2 (he) |
ZA (1) | ZA200210109B (he) |
Families Citing this family (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0996725A1 (en) * | 1997-06-27 | 2000-05-03 | Human Genome Sciences, Inc. | Human nk-3 related prostate specific gene-1 |
CN1451043A (zh) | 2000-06-29 | 2003-10-22 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ATE477280T1 (de) * | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
GB0115841D0 (en) | 2001-06-28 | 2001-08-22 | Medical Res Council | Ligand |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US9028822B2 (en) | 2002-06-28 | 2015-05-12 | Domantis Limited | Antagonists against TNFR1 and methods of use therefor |
US20070104710A1 (en) * | 2002-06-28 | 2007-05-10 | Domants Limited | Ligand that has binding specificity for IL-4 and/or IL-13 |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
CN101537180B (zh) | 2002-07-18 | 2016-02-10 | 莫鲁斯有限公司 | 抗体混合物的重组生产 |
US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
US20110223168A1 (en) * | 2002-12-27 | 2011-09-15 | Greg Winter | Ligand that has binding specificity for il-4 and/or il-13 |
GB0230201D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Retargeting |
ES2408582T3 (es) | 2003-05-30 | 2013-06-21 | Merus B.V. | Biblioteca de Fab para la preparación de una mezcla de anticuerpos |
US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
CA2553692C (en) * | 2004-01-20 | 2014-10-07 | Kalobios, Inc. | Antibody specificity transfer using minimal essential binding determinants |
DK1737971T3 (da) | 2004-01-20 | 2017-11-13 | Merus Nv | Blandinger af bindingsproteiner |
TWI556829B (zh) | 2004-04-09 | 2016-11-11 | 艾伯維生物技術有限責任公司 | 用於治療TNFα相關失調症之多重可變劑量療法 |
US7514539B2 (en) | 2004-04-26 | 2009-04-07 | Centocor, Inc. | Epitope directed selection of antibodies to murine tissue factor |
US7790405B2 (en) | 2004-04-26 | 2010-09-07 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
WO2005117969A2 (en) * | 2004-04-26 | 2005-12-15 | Centocor, Inc. | Solution phase biopanning method using engineered decoy proteins |
AU2005250216B2 (en) | 2004-06-01 | 2009-12-10 | Domantis Limited | Bispecific fusion antibodies with enhanced serum half-life |
EP1851245B1 (en) | 2005-01-26 | 2012-10-10 | Amgen Fremont Inc. | Antibodies against interleukin-1 beta |
KR100675791B1 (ko) * | 2005-02-04 | 2007-02-02 | 제주대학교 산학협력단 | 육상어류양식장용 자동먹이공급시스템 |
ATE507242T1 (de) * | 2005-05-12 | 2011-05-15 | Crucell Holland Bv | Wirtszellenspezifische bindungsmoleküle, die dazu in der lage sind, viren zu neutralisieren, und anwendungen davon |
US20090130652A1 (en) * | 2005-06-23 | 2009-05-21 | Crucell Holland B.V. | Optimization of West Nile Virus Antibodies |
NI200800032A (es) | 2005-07-25 | 2009-03-23 | Reducción de célula b utilizando moléculas de unión específicas cd37 y cd20 | |
EP2500359A3 (en) | 2005-08-19 | 2012-10-17 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
EP2500352A1 (en) | 2005-08-19 | 2012-09-19 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
ES2542501T3 (es) | 2005-09-30 | 2015-08-06 | Abbvie Deutschland Gmbh & Co Kg | Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso |
US20100015146A1 (en) * | 2005-10-14 | 2010-01-21 | Novo Nordisk A/S | Treating diabetes using inhibitors of il-1 |
US20100047204A1 (en) * | 2006-04-14 | 2010-02-25 | Dana Sue Yoo | Use of organic compounds |
CA2881717C (en) * | 2006-06-06 | 2018-06-12 | Cecilia Anna Wilhelmina Geuijen | Human binding molecules having killing activity against staphylococci and uses thereof |
MX2008015524A (es) | 2006-06-12 | 2009-01-13 | Trubion Pharmaceuticals Inc | Proteinas de union multivalentes monocatenarias con funcion efectora. |
CA2659745A1 (en) * | 2006-08-02 | 2008-02-07 | California Institute Of Technology | Methods and systems for detecting and/or sorting targets |
WO2008027236A2 (en) * | 2006-08-30 | 2008-03-06 | Genentech, Inc. | Multispecific antibodies |
EP2094306A2 (en) * | 2006-12-20 | 2009-09-02 | XOMA Technology Ltd. | Treatment of il-1-beta related diseases |
US8324350B2 (en) | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
US8092998B2 (en) | 2007-05-31 | 2012-01-10 | Abbott Laboratories | Biomarkers predictive of the responsiveness to TNFα inhibitors in autoimmune disorders |
EP2195341B1 (en) | 2007-09-26 | 2017-03-22 | UCB Biopharma SPRL | Dual specificity antibody fusions |
CA2707637A1 (en) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
JP2011517662A (ja) | 2008-03-03 | 2011-06-16 | ダイアックス コーポレーション | メタロプロテアーゼ9結合タンパク質 |
WO2009111508A2 (en) * | 2008-03-03 | 2009-09-11 | Dyax Corp. | Metalloproteinase 9 and metalloproteinase 2 binding proteins |
SI2132228T1 (sl) | 2008-04-11 | 2011-10-28 | Emergent Product Dev Seatle | CD37 imunoterapevtik in kombinacija z njegovim bifunkcionalnim kemoterapevtikom |
US20100260668A1 (en) * | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
US9029508B2 (en) | 2008-04-29 | 2015-05-12 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
CN102112494A (zh) | 2008-06-03 | 2011-06-29 | 雅培制药有限公司 | 双重可变结构域免疫球蛋白及其用途 |
EP3002299A1 (en) | 2008-06-03 | 2016-04-06 | AbbVie Inc. | Dual variable domain immunoglobulins and uses thereof |
JP5674654B2 (ja) | 2008-07-08 | 2015-02-25 | アッヴィ・インコーポレイテッド | プロスタグランジンe2二重可変ドメイン免疫グロブリンおよびその使用 |
US8193321B2 (en) | 2008-09-03 | 2012-06-05 | Genentech, Inc. | Multispecific antibodies |
JP2012502059A (ja) * | 2008-09-05 | 2012-01-26 | ゾーマ テクノロジー リミテッド | IL−1β関連疾患を処置または予防するための方法 |
CN102209557A (zh) * | 2008-09-12 | 2011-10-05 | 埃克斯生物科技公司 | 靶向病原性单核细胞 |
WO2010035012A1 (en) | 2008-09-26 | 2010-04-01 | Ucb Pharma S.A. | Biological products |
EP2196476A1 (en) * | 2008-12-10 | 2010-06-16 | Novartis Ag | Antibody formulation |
PE20120586A1 (es) * | 2009-01-29 | 2012-06-17 | Abbott Lab | Proteinas de union a il-1 |
EP2810652A3 (en) | 2009-03-05 | 2015-03-11 | AbbVie Inc. | IL-17 binding proteins |
CA2756244A1 (en) * | 2009-04-02 | 2010-10-07 | Roche Glycart Ag | Multispecific antibodies comprising full length antibodies and single chain fab fragments |
CN101957365B (zh) * | 2009-07-21 | 2013-08-07 | 卫生部北京医院 | 检测抗环瓜氨酸肽和抗免疫球蛋白g双特异性抗体的试剂盒 |
TW201109438A (en) * | 2009-07-29 | 2011-03-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US8623358B2 (en) | 2009-08-29 | 2014-01-07 | Abbvie Inc. | Therapeutic DLL4 binding proteins |
EP2473524A4 (en) * | 2009-09-01 | 2013-05-22 | Abbott Lab | IMMUNOGLOBULINE WITH DOUBLE VARIABLE DOMAIN AND ITS USE |
GB201005063D0 (en) | 2010-03-25 | 2010-05-12 | Ucb Pharma Sa | Biological products |
JP2013507929A (ja) * | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | Il−1結合蛋白質 |
KR20140015139A (ko) | 2009-10-15 | 2014-02-06 | 애브비 인코포레이티드 | 이원 가변 도메인 면역글로불린 및 이의 용도 |
UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
SG181563A1 (en) | 2009-12-08 | 2012-07-30 | Abbott Gmbh & Co Kg | Monoclonal antibodies against the rgm a protein for use in the treatment of retinal nerve fiber layer degeneration |
US20130045209A1 (en) * | 2010-01-12 | 2013-02-21 | Oncomed Pharmaceuticals, Inc. | WNT-Binding Agents and Uses Thereof |
EP2542582A4 (en) | 2010-03-02 | 2013-12-04 | Abbvie Inc | THERAPEUTIC PROTEINS LINKING TO DLL4 |
TWI586806B (zh) * | 2010-04-23 | 2017-06-11 | 建南德克公司 | 異多聚體蛋白質之製造 |
AU2011252883B2 (en) | 2010-05-14 | 2015-09-10 | Abbvie Inc. | IL-1 binding proteins |
WO2012006500A2 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (es) | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
CN103298834A (zh) | 2010-08-03 | 2013-09-11 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
JP2013537539A (ja) * | 2010-08-13 | 2013-10-03 | ジェネンテック, インコーポレイテッド | 疾患の治療のためのIL−1β及びIL−18に対する抗体 |
BR112013004581A2 (pt) | 2010-08-26 | 2017-06-27 | Abbvie Inc | imunoglobulinas de domínio variável dual e seus usos |
KR20130133247A (ko) | 2010-12-21 | 2013-12-06 | 애브비 인코포레이티드 | Il-1-알파 및 -베타 이특이적 이원 가변 도메인 면역글로불린 및 이의 용도 |
KR20130130825A (ko) | 2011-02-08 | 2013-12-02 | 애브비 인코포레이티드 | 골관절염 및 통증의 치료 방법 |
EP2726506A1 (en) | 2011-05-27 | 2014-05-07 | Dutalys | Removal of monomeric targets |
EP2726510B1 (en) | 2011-05-27 | 2023-03-08 | F. Hoffmann-La Roche AG | Dual targeting |
CA2840461A1 (en) | 2011-06-20 | 2012-12-27 | Kyowa Hakko Kirin Co., Ltd. | Anti-erbb3 antibody |
US10314909B2 (en) | 2011-10-21 | 2019-06-11 | Dyax Corp. | Combination therapy comprising an MMP-14 binding protein |
WO2013063095A1 (en) | 2011-10-24 | 2013-05-02 | Abbvie Inc. | Immunobinders directed against sclerostin |
AU2012328917B2 (en) | 2011-10-24 | 2017-05-25 | Abbvie Inc. | Bispecific immunobinders directed against TNF and IL-17 |
JP2015500206A (ja) * | 2011-11-21 | 2015-01-05 | アッヴィ・インコーポレイテッド | Il−1結合タンパク質 |
RU2482181C1 (ru) * | 2011-12-07 | 2013-05-20 | Учреждение Российской академии медицинских наук Российский онкологический научный центр имени Н.Н. Блохина РАМН | Клеточная линия d11 множественной миеломы человека, используемая для гибридомной технологии |
CA2855840C (en) | 2011-12-14 | 2023-08-29 | AbbVie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
EP2791175A2 (en) | 2011-12-14 | 2014-10-22 | Abbvie Deutschland GmbH & Co. KG | Composition and method for the diagnosis and treatment of iron-related disorders |
KR101963230B1 (ko) | 2011-12-26 | 2019-03-29 | 삼성전자주식회사 | 복수개의 단일 항체를 포함하는 단백질 복합체 |
AR089529A1 (es) | 2011-12-30 | 2014-08-27 | Abbvie Inc | Proteinas de union especificas duales dirigidas contra il-13 y/o il-17 |
AR090047A1 (es) | 2011-12-30 | 2014-10-15 | Abbvie Inc | Dominio variable dual de inmunoglobulinas y sus usos |
RU2644337C2 (ru) | 2012-01-27 | 2018-02-08 | Эббви Дойчланд Гмбх Унд Ко. Кг | Композиции и способы диагностики и лечения заболеваний, ассоциированных с дегенерацией нейритов |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
PT2838918T (pt) | 2012-04-20 | 2019-08-23 | Merus Nv | Métodos e meios para a produção de moléculas heterrodiméricas do tipo ig |
WO2014011955A2 (en) | 2012-07-12 | 2014-01-16 | Abbvie, Inc. | Il-1 binding proteins |
KR101911438B1 (ko) | 2012-10-31 | 2018-10-24 | 삼성전자주식회사 | 이중 특이 항원 결합 단백질 복합체 및 이중 특이 항체의 제조 방법 |
CA2889488A1 (en) * | 2012-11-01 | 2014-05-08 | Abbvie Inc. | Stable dual variable domain immunoglobulin protein formulations |
PE20151179A1 (es) | 2012-11-01 | 2015-09-12 | Abbvie Inc | Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas |
WO2014089209A2 (en) | 2012-12-04 | 2014-06-12 | Abbvie, Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins |
WO2014106001A2 (en) | 2012-12-28 | 2014-07-03 | Abbvie, Inc. | Dual specific binding proteins having a receptor sequence |
EP2938636A2 (en) | 2012-12-28 | 2015-11-04 | AbbVie Inc. | High-throughput system and method for identifying antibodies having specific antigen binding activities |
US9856319B2 (en) | 2012-12-28 | 2018-01-02 | Abbvie Inc. | Monovalent binding proteins |
EP2948475A2 (en) | 2013-01-23 | 2015-12-02 | AbbVie Inc. | Methods and compositions for modulating an immune response |
BR112015023797A2 (pt) | 2013-03-15 | 2017-10-24 | Abbvie Inc | proteínas de ligação de especificidade dupla dirigidas contra il-1b e/ou il-17 |
US9469686B2 (en) | 2013-03-15 | 2016-10-18 | Abbott Laboratories | Anti-GP73 monoclonal antibodies and methods of obtaining the same |
TW201446800A (zh) | 2013-03-15 | 2014-12-16 | Abbvie Inc | 針對TNFα之雙特異性結合蛋白 |
US10183988B2 (en) | 2013-06-07 | 2019-01-22 | Duke University | Anti-Complement factor H antibodies |
CN103308697B (zh) * | 2013-06-09 | 2014-11-26 | 卫生部北京医院 | 检测抗丙型肝炎病毒编码的非结构蛋白ns3和ns5的天然双特异性抗体的试剂盒 |
US9879081B2 (en) | 2013-06-25 | 2018-01-30 | Samsung Electronics Co., Ltd. | Protein complex, bispecific antibody including the protein complex, and method of preparation thereof |
JP2016533318A (ja) | 2013-09-17 | 2016-10-27 | ユニバーシティ ヘルス ネットワーク (ユーエイチエヌ): テクノロジー ディベロップメント アンド コマーシャリゼーション | Rgma/ネオジェニンのシス相互作用又は脂質ラフトを標的とする剤及び治療方法における該剤の使用 |
EP3940065A1 (en) * | 2013-09-30 | 2022-01-19 | Chugai Seiyaku Kabushiki Kaisha | Method for producing antigen-binding molecule using modified helper phage |
MX2016006529A (es) * | 2013-12-20 | 2016-08-03 | Genentech Inc | Anticuerpos dobles especificos. |
WO2015191783A2 (en) | 2014-06-10 | 2015-12-17 | Abbvie Inc. | Biomarkers for inflammatory disease and methods of using same |
WO2015191934A2 (en) | 2014-06-11 | 2015-12-17 | Abbvie Inc. | Blood-brain barrier (bbb) penetrating dual specific binding proteins for treating brain and neurological diseases |
EP2985294A1 (en) | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
JP6655302B2 (ja) * | 2015-05-29 | 2020-02-26 | デンカ生研株式会社 | 被検対象の検出方法並びにそのための免疫測定器具及びモノクローナル抗体 |
TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗vegf、pdgf及/或其受體之結合蛋白 |
WO2017044862A1 (en) | 2015-09-11 | 2017-03-16 | Abbvie Inc. | Methods for treating relapsing forms of multiple sclerosis |
WO2017053469A2 (en) | 2015-09-21 | 2017-03-30 | Aptevo Research And Development Llc | Cd3 binding polypeptides |
EP3356821B1 (en) * | 2015-10-02 | 2019-10-23 | H. Hoffnabb-La Roche Ag | Cellular based fret assay for the determination of simultaneous binding |
CR20180161A (es) | 2015-10-02 | 2018-05-25 | Hoffmann La Roche | Anticuerpos biespecíficos para pd1 y tim3 |
WO2017087768A1 (en) | 2015-11-18 | 2017-05-26 | Duke University | Targeted delivery of interleukin-10 to tumor infiltrating lymphocytes |
SG11201807176XA (en) | 2016-03-11 | 2018-09-27 | Scholar Rock Inc | TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF |
JP2019517480A (ja) | 2016-06-01 | 2019-06-24 | アッヴィ・インコーポレイテッド | 脊髄損傷及び疼痛を処置するための抗RGMa(Repulsive Guidance Molecule A)アンタゴニスト抗体 |
US20180106800A1 (en) | 2016-10-03 | 2018-04-19 | Abbott Laboratories | Methods of assessing uch-l1 status in patient samples |
AU2018205231A1 (en) | 2017-01-06 | 2019-07-18 | Scholar Rock, Inc. | Isoform-specific, context-permissive TGFβ1 inhibitors and use thereof |
CA3052513A1 (en) | 2017-03-23 | 2018-09-27 | Abbott Laboratories | Methods for aiding in the diagnosis and determination of the extent of traumatic brain injury in a human subject using the early biomarker ubiquitin carboxy-terminal hydrolase l1 |
PL3606946T3 (pl) | 2017-04-03 | 2022-11-28 | F. Hoffmann-La Roche Ag | Immunokoniugaty przeciwciała anty-PD-1 ze zmutowaną IL-2 lub z IL-15 |
BR112019019821A2 (pt) | 2017-04-05 | 2020-04-22 | Hoffmann La Roche | anticorpo biespecífico, polinucleotídeo, célula hospedeira procariótica ou eucariótica, métodos de produção do anticorpo biespecífico, de tratamento de um indivíduo que tem câncer ou uma infecção viral crônica e de inibição do crescimento de células de tumor, composição farmacêutica e uso do anticorpo biespecífico |
EP3610268A1 (en) | 2017-04-15 | 2020-02-19 | Abbott Laboratories | Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers |
JP7080899B2 (ja) | 2017-04-28 | 2022-06-06 | アボット・ラボラトリーズ | 同じヒト対象に由来する少なくとも2つの試料に対して早期バイオマーカーを使用する、外傷性脳損傷の超急性の診断及び決定の一助となるための方法 |
US10865238B1 (en) | 2017-05-05 | 2020-12-15 | Duke University | Complement factor H antibodies |
CA3078725A1 (en) | 2017-05-25 | 2018-11-29 | Abbott Laboratories | Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers |
AU2018275236A1 (en) | 2017-05-30 | 2019-10-31 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a mild traumatic brain injury in a human subject using cardiac troponin I |
US11169159B2 (en) | 2017-07-03 | 2021-11-09 | Abbott Laboratories | Methods for measuring ubiquitin carboxy-terminal hydrolase L1 levels in blood |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
CA3081854A1 (en) | 2017-11-08 | 2019-05-16 | Kyowa Kirin Co., Ltd. | Bispecific antibody which binds to cd40 and epcam |
AU2018378084A1 (en) | 2017-12-09 | 2020-05-14 | Abbott Laboratories | Methods for aiding in diagnosing and evaluating a traumatic brain injury in a human subject using a combination of GFAP and UCH-L1 |
BR112019028254A2 (pt) | 2017-12-09 | 2020-07-14 | Abbott Laboratories | métodos para ajudar no diagnóstico e avaliação de um paciente que sofreu uma lesão ortopédica e que sofreu ou pode ter sofrido uma lesão na cabeça, tal como uma lesão cerebral traumática (lct) leve, usando a proteína ácida fibrilar glial (gfap) e/ou a hidrolase carbóxi-terminal da ubiquitina l1 (uch-l1) |
EP3732489A1 (en) | 2017-12-29 | 2020-11-04 | Abbott Laboratories | Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury |
SG11202013231SA (en) | 2018-07-11 | 2021-01-28 | Scholar Rock Inc | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF |
EP3820896A1 (en) | 2018-07-11 | 2021-05-19 | Scholar Rock, Inc. | TGFbeta1 INHIBITORS AND USE THEREOF |
SI3677278T1 (sl) | 2018-07-11 | 2022-01-31 | Scholar Rock, Inc. | Izoformno selektivni zaviralci TGFBETA1 in uporaba le-teh |
CA3125316A1 (en) | 2018-12-28 | 2020-07-02 | Kyowa Kirin Co., Ltd. | Bispecific antibody binding to tfr |
EP3931573A1 (en) | 2019-03-01 | 2022-01-05 | Abbott Laboratories | Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease |
TW202108626A (zh) | 2019-05-15 | 2021-03-01 | 日商協和麒麟股份有限公司 | 與cd40及fap結合之雙專一性抗體 |
JPWO2020230901A1 (he) | 2019-05-15 | 2020-11-19 | ||
CA3167427A1 (en) | 2020-01-11 | 2021-07-15 | Scholar Rock, Inc. | Tgfb inhibitors and use thereof |
AU2021205440A1 (en) | 2020-01-11 | 2022-09-01 | Scholar Rock,Inc. | TGF-beta inhibitors and use thereof |
EP4136459A1 (en) | 2020-04-13 | 2023-02-22 | Abbott Laboratories | Methods, complexes and kits for detecting or determining an amount of a ss-coronavirus antibody in a sample |
CN111793131A (zh) * | 2020-05-11 | 2020-10-20 | 廊坊天光生物技术有限公司 | 一种用于检测血清中pf4含量的抗体对及其用途 |
WO2022031804A1 (en) | 2020-08-04 | 2022-02-10 | Abbott Laboratories | Improved methods and kits for detecting sars-cov-2 protein in a sample |
WO2023102384A1 (en) | 2021-11-30 | 2023-06-08 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi |
US20220170948A1 (en) | 2020-12-01 | 2022-06-02 | Abbott Laboratories | Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi |
WO2022147147A1 (en) | 2020-12-30 | 2022-07-07 | Abbott Laboratories | Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample |
WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
BR112023024169A2 (pt) | 2021-05-18 | 2024-02-06 | Abbott Lab | Métodos para avaliar lesão cerebral em um indivíduo pediátrico |
WO2022256723A2 (en) | 2021-06-03 | 2022-12-08 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
EP4356129A1 (en) | 2021-06-14 | 2024-04-24 | Abbott Laboratories | Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind |
EP4370148A1 (en) | 2021-07-14 | 2024-05-22 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf beta1 and uses thereof |
WO2023019019A2 (en) * | 2021-08-13 | 2023-02-16 | Abwiz Bio, Inc. | Humanization, affinity maturation, and optimization methods for proteins and antibodies |
WO2023034777A1 (en) | 2021-08-31 | 2023-03-09 | Abbott Laboratories | Methods and systems of diagnosing brain injury |
CA3232176A1 (en) | 2021-09-30 | 2023-04-06 | Beth MCQUISTON | Methods and systems of diagnosing brain injury |
WO2023114978A1 (en) | 2021-12-17 | 2023-06-22 | Abbott Laboratories | Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples |
US20230213536A1 (en) | 2021-12-28 | 2023-07-06 | Abbott Laboratories | Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan |
WO2023150652A1 (en) | 2022-02-04 | 2023-08-10 | Abbott Laboratories | Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample |
WO2024006876A1 (en) | 2022-06-29 | 2024-01-04 | Abbott Laboratories | Magnetic point-of-care systems and assays for determining gfap in biological samples |
WO2024059708A1 (en) | 2022-09-15 | 2024-03-21 | Abbott Laboratories | Biomarkers and methods for differentiating between mild and supermild traumatic brain injury |
Family Cites Families (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US126603A (en) | 1872-05-07 | Improvement in machines for sawing staves | ||
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
FR2577377B1 (fr) * | 1985-02-21 | 1989-06-16 | Albaret Sa | Procede pour eviter le patinage d'un tracteur equipe d'un relevage hydraulique avec un outil enfoui dans le sol, et equipement de tracteur pour mettre en oeuvre ce procede |
US4772685A (en) * | 1985-10-02 | 1988-09-20 | Merck & Co., Inc. | Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
JP3771253B2 (ja) | 1988-09-02 | 2006-04-26 | ダイアックス コープ. | 新規な結合タンパク質の生成と選択 |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
JP2919890B2 (ja) | 1988-11-11 | 1999-07-19 | メディカル リサーチ カウンスル | 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用 |
DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
EP0585287B1 (en) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1992002551A1 (en) | 1990-08-02 | 1992-02-20 | B.R. Centre Limited | Methods for the production of proteins with a desired function |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
PT1024191E (pt) | 1991-12-02 | 2008-12-22 | Medical Res Council | Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos |
DE69333447T2 (de) * | 1992-05-22 | 2009-09-10 | Montana State University, Bozeman | Antikörper mit spezifikäten gegen mehrere adhäsionsmoleküle |
US5622701A (en) * | 1994-06-14 | 1997-04-22 | Protein Design Labs, Inc. | Cross-reacting monoclonal antibodies specific for E- and P-selectin |
JPH10503179A (ja) * | 1994-06-24 | 1998-03-24 | イミュネックス・コーポレーション | 放出制御性ポリペプチド組成物および炎症性腸疾患の治療方法 |
ATE390933T1 (de) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8 |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
CN1300173C (zh) | 1996-02-09 | 2007-02-14 | 艾博特生物技术有限公司 | 结合人TNFα的人抗体 |
US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
IL119587A (en) * | 1996-11-07 | 2000-12-06 | Univ Ramot | Method of preparing and for obtaining bimolecular interactions |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
KR100566859B1 (ko) | 1997-01-21 | 2006-04-03 | 제너럴 하스피톨 코포레이션 | Rna-단백질 융합물을 이용한 단백질의 선별 |
JP2002514919A (ja) | 1997-04-04 | 2002-05-21 | バイオサイト ダイアグノスティックス,インコーポレイテッド | 多価ライブラリーおよびポリクローナルライブラリー |
WO1998049286A2 (en) | 1997-05-01 | 1998-11-05 | Board Of Regents, The University Of Texas System | Directed evolution of enzymes and antibodies |
US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
US6680380B1 (en) * | 1998-09-18 | 2004-01-20 | Schering Corporation | Nucleic acids encoding mammalian interleukin-1ζ, related reagents and methods |
NZ592550A (en) | 1999-03-25 | 2012-12-21 | Abbott Gmbh & Co Kg | Compostion comprising antibody capable of binding to p40 subunit of IL-12 |
GB0001448D0 (en) | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
CN1451043A (zh) * | 2000-06-29 | 2003-10-22 | 艾博特公司 | 双特异性抗体及其制备方法和用途 |
ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
JP2006512895A (ja) * | 2002-06-28 | 2006-04-20 | ドマンティス リミテッド | リガンド |
CA2632866A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Noncompetitive domain antibody formats that bind interleukin 1 receptor type 1 |
US8324350B2 (en) * | 2006-12-29 | 2012-12-04 | Abbott Laboratories | Dual-specific IL-1α/IL-1β antibodies |
-
2001
- 2001-06-28 CN CN01814818A patent/CN1451043A/zh active Pending
- 2001-06-28 CA CA2411374A patent/CA2411374C/en not_active Expired - Fee Related
- 2001-06-28 IL IL15356701A patent/IL153567A0/xx unknown
- 2001-06-28 EP EP01950668A patent/EP1297142B1/en not_active Expired - Lifetime
- 2001-06-28 CN CN2010105838125A patent/CN102120773B/zh not_active Expired - Fee Related
- 2001-06-28 KR KR1020087018593A patent/KR20080074231A/ko not_active Application Discontinuation
- 2001-06-28 EP EP15154039.0A patent/EP2899210A3/en not_active Withdrawn
- 2001-06-28 UY UY26807A patent/UY26807A1/es not_active Application Discontinuation
- 2001-06-28 EP EP09150437A patent/EP2042518A3/en not_active Withdrawn
- 2001-06-28 US US09/894,550 patent/US7491516B2/en not_active Expired - Fee Related
- 2001-06-28 AU AU2001271636A patent/AU2001271636A1/en not_active Abandoned
- 2001-06-28 ES ES01950668T patent/ES2319866T3/es not_active Expired - Lifetime
- 2001-06-28 CZ CZ2003291A patent/CZ2003291A3/cs unknown
- 2001-06-28 PE PE2001000641A patent/PE20020132A1/es not_active Application Discontinuation
- 2001-06-28 AT AT01950668T patent/ATE420958T1/de not_active IP Right Cessation
- 2001-06-28 KR KR1020027017916A patent/KR100919593B1/ko not_active IP Right Cessation
- 2001-06-28 SK SK115-2003A patent/SK1152003A3/sk not_active Application Discontinuation
- 2001-06-28 MX MXPA02012867A patent/MXPA02012867A/es active IP Right Grant
- 2001-06-28 PL PL359995A patent/PL208069B1/pl not_active IP Right Cessation
- 2001-06-28 DE DE60137421T patent/DE60137421D1/de not_active Expired - Lifetime
- 2001-06-28 HU HU0301002A patent/HUP0301002A3/hu unknown
- 2001-06-28 BR BR0112026-3A patent/BR0112026A/pt not_active IP Right Cessation
- 2001-06-28 NZ NZ523080A patent/NZ523080A/en not_active IP Right Cessation
- 2001-06-28 JP JP2002508013A patent/JP4955185B2/ja not_active Expired - Fee Related
- 2001-06-28 EP EP10182393A patent/EP2386575A3/en not_active Withdrawn
- 2001-06-28 CN CNA2009101351381A patent/CN101525384A/zh active Pending
- 2001-06-28 WO PCT/US2001/020755 patent/WO2002002773A2/en active Application Filing
- 2001-06-29 TW TW090115948A patent/TWI307716B/zh not_active IP Right Cessation
- 2001-06-29 TW TW094102248A patent/TW200516083A/zh unknown
-
2002
- 2002-12-12 ZA ZA200210109A patent/ZA200210109B/en unknown
- 2002-12-20 IL IL153567A patent/IL153567A/he not_active IP Right Cessation
- 2002-12-27 NO NO20026239A patent/NO20026239L/no not_active Application Discontinuation
- 2002-12-27 EC EC2002004409A patent/ECSP024409A/es unknown
-
2003
- 2003-01-21 BG BG107483A patent/BG66209B1/bg unknown
- 2003-08-27 HK HK03106152.8A patent/HK1055316A1/xx unknown
-
2008
- 2008-12-11 US US12/316,340 patent/US8475766B2/en not_active Expired - Lifetime
-
2010
- 2010-02-14 IL IL203955A patent/IL203955A/he not_active IP Right Cessation
-
2011
- 2011-08-31 JP JP2011188635A patent/JP2012031178A/ja active Pending
-
2013
- 2013-05-23 US US13/900,841 patent/US20140155579A1/en not_active Abandoned
-
2014
- 2014-08-26 US US14/469,122 patent/US20140378666A1/en not_active Abandoned
-
2015
- 2015-03-05 US US14/639,985 patent/US20150175694A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL153567A0 (en) | Dual specificity antibodies and methods of making and using | |
PL356836A1 (en) | Antibodies that bind human interleukin-18 and methods of making and using | |
LU92159I2 (fr) | Ustekinumab et ses dérivés pharmaceutiquement acceptables (STELARA®) | |
IL206979A0 (en) | Il-18 binding proteins | |
NO2017038I2 (no) | Adalimumab - Forlenget SPC | |
HUP0302589A2 (hu) | A béta-amiloid peptidet felismerő humanizált ellenanyagok | |
EP0536275A4 (en) | Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof | |
ZA945364B (en) | Antibodies specific for human prostate glandular kallikrein | |
EP1411962A4 (en) | MONOCLONAL ANTIBODY TREATMENT OF PANCREATIC CANCER | |
WO2003011907A3 (de) | Rezeptor, dessen verwendung sowie mausantikörper |